Compare LMFA & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | GRI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.6M |
| IPO Year | 2015 | 2020 |
| Metric | LMFA | GRI |
|---|---|---|
| Price | $2.60 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 1.4M | 93.3K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,844,733.00 | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.18 |
| 52 Week High | $4.75 | $6.70 |
| Indicator | LMFA | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 81.13 | 33.29 |
| Support Level | $0.24 | $0.20 |
| Resistance Level | $3.40 | $2.27 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 77.43 | 19.15 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining and Treasury Operations.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.